AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting treatments for mental health conditions, formed from the combination of atai Life Sciences and Beckley Psytech. Its pipeline includes candidates such as an intranasal mebufotenin formulation for treatment-resistant depression, a DMT-based film and an (R)-MDMA program for social anxiety, among other psychedelic- and neuromodulator-based approaches. The focus is on therapies intended to be robust, durable and suitable for broader clinical use.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1.6 | — | -26.4 | — |
| Q2 2025 | 0.7 | — | -27.7 | — |
| Q3 2025 | 0.8 | — | -61.1 | — |
| Q4 2025 | 1.1 | — | -544.8 | — |
| Q1 2026 | 0.9 | -38.6% | -29.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Visteon Corporation (VC), Slide Insurance Holdings, Inc. (SLDE), Trump Media & Technology Group Corp. (DJT), Veeco Instruments Inc. (VECO), TMC the metals company Inc. (TMC), SELLAS Life Sciences Group, Inc. (SLS)